Spruce Biosciences Expands Innovative Treatments for Congenital Adrenal Hyperplasia with Tildacerfont Trials

Spruce Biosciences Advances Treatment Options for Congenital Adrenal Hyperplasia

Spruce Biosciences, Inc., a late-stage biopharmaceutical company, is significantly advancing its research and development efforts in the field of congenital adrenal hyperplasia (CAH). The company’s CEO, Javier Szwarcberg, underscores Spruce's commitment to the CAH community, announcing that primary efficacy and safety data from the CAHmelia-204 study of tildacerfont in adult CAH patients is anticipated in December 2024. This Phase 2b clinical trial evaluates the safety and efficacy of a daily 200mg dose of tildacerfont, aiming to reduce excessive glucocorticoid (GC) use among participants. With a focus on the primary endpoint of change in daily GC dose from baseline to week 24, the study involves 90 adult patients and is pivotal for developing more effective treatment strategies for this condition.

In addition to the CAHmelia-204 study, Spruce is conducting the CAHptain-205 study, which is a Phase 2 open-label trial examining the pharmacokinetics and efficacy of tildacerfont in both adults and pediatric patients aged 2 to 17. This study employs a sequential cohort design, initially testing weight-adjusted doses ranging from 50mg to 200mg once daily in pediatric patients. The trial then progresses to evaluate higher dosages of 200mg and 400mg administered twice daily, reflecting Spruce’s comprehensive approach to addressing the diverse needs of CAH patients across different age groups. These studies are crucial for understanding how tildacerfont can effectively reduce androgen levels and taper GCs, which are commonly used in CAH management.

Spruce Biosciences is dedicated to enhancing treatment options for the CAH community by actively collaborating with stakeholders and patients. The company's focus on innovative therapies is not only about meeting clinical needs but also involves engaging with the community to improve management strategies for CAH. By prioritizing patient-centric research, Spruce aims to deliver therapies that significantly improve the quality of life for those affected by this condition.

In its recent financial results for the third quarter ended September 30, 2024, Spruce highlights its ongoing commitment to research and development despite the challenges inherent in the biopharmaceutical landscape. As the company prepares for the upcoming data releases from its clinical trials, it remains focused on its mission to provide innovative solutions for endocrine and neurological disorders. The anticipated results from both studies could mark a turning point in the treatment landscape for CAH, demonstrating Spruce's role as a leader in this vital area of healthcare.